\BOOKMARK [0][-]{part.1}{I Introducci\363}{}% 1
\BOOKMARK [1][-]{section.1}{Introducci\363}{part.1}% 2
\BOOKMARK [2][-]{subsection.1.1}{Hist\362ria}{section.1}% 3
\BOOKMARK [2][-]{subsection.1.2}{Mutacions}{section.1}% 4
\BOOKMARK [2][-]{subsection.1.3}{Malalties monog\350niques}{section.1}% 5
\BOOKMARK [2][-]{subsection.1.4}{Diagn\362stic}{section.1}% 6
\BOOKMARK [2][-]{subsection.1.5}{Malalties monog\350niques per p\350rdua de funci\363}{section.1}% 7
\BOOKMARK [1][-]{section.2}{Malalties autos\362miques recessives}{part.1}% 8
\BOOKMARK [2][-]{subsection.2.1}{Intoler\340ncia a la lactosa}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.2}{Intoler\340ncia heredit\340ria a la galactosa}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.3}{Intoler\340ncia heredit\340ria a la fructosa}{section.2}% 11
\BOOKMARK [2][-]{subsection.2.4}{Defici\350ncia en 21-hidroxilasa}{section.2}% 12
\BOOKMARK [2][-]{subsection.2.5}{Gota}{section.2}% 13
\BOOKMARK [2][-]{subsection.2.6}{Malaltia de Pompe}{section.2}% 14
\BOOKMARK [1][-]{section.3}{Malalties autos\362miques dominants}{part.1}% 15
\BOOKMARK [2][-]{subsection.3.1}{S\355ndrome de defici\350ncia de GLUT1}{section.3}% 16
\BOOKMARK [2][-]{subsection.3.2}{Polineuropatia amilod\362ptica familiar de tipus I}{section.3}% 17
\BOOKMARK [2][-]{subsection.3.3}{S\355ndrome de resist\350ncia generalitzada a les hormones tiro\357dals}{section.3}% 18
\BOOKMARK [2][-]{subsection.3.4}{Osteog\350nesi imperfecta}{section.3}% 19
\BOOKMARK [2][-]{subsection.3.5}{Cribatge neonatal}{section.3}% 20
\BOOKMARK [2][-]{subsection.3.6}{Cribatge en adults}{section.3}% 21
\BOOKMARK [1][-]{section.4}{Malalties del genoma mitocondrial}{part.1}% 22
\BOOKMARK [2][-]{subsection.4.1}{Biologia del DNA mitocondrial}{section.4}% 23
\BOOKMARK [2][-]{subsection.4.2}{Mutacions al genoma mitocondrial}{section.4}% 24
\BOOKMARK [2][-]{subsection.4.3}{Her\350ncia del genoma mitocondrial}{section.4}% 25
\BOOKMARK [2][-]{subsection.4.4}{Malalties mitocondrials}{section.4}% 26
\BOOKMARK [1][-]{section.5}{Seminari. Lipodistr\362fies cong\350nites}{part.1}% 27
\BOOKMARK [2][-]{subsection.5.1}{Lipodistr\362fies cong\350nites}{section.5}% 28
\BOOKMARK [2][-]{subsection.5.2}{Bases moleculars de les lipodistr\362fies cong\350nites generalitzades}{section.5}% 29
